

PATRICK J. LEAHY, VERMONT, CHAIRMAN

HERB KOHL, WISCONSIN
DIANNE FEINSTEIN, CALIFORNIA
CHARLES E. SCHUMER, NEW YORK
RICHARD J. DURBIN, ILLINOIS
SHELDON WHITEHOUSE, RHODE ISLAND
AMY KLOBUCHAR, MINNESOTA
AL FRANKEN, MINNESOTA
CHRISTOPHER A. COONS, DELAWARE
RICHARD BLUMENTHAL, CONNECTICUT

CHARLES E. GRASSLEY, IOWA
ORRIN G. HATCH, UTAH
JON KYL, ARIZONA
JEFF SESSIONS, ALABAMA
LINDSEY O. GRAHAM, SOUTH CAROLINA
JOHN CORNYN, TEXAS
MICHAEL S. LEE, UTAH
TOM COBURN, OKLAHOMA

United States Senate

COMMITTEE ON THE JUDICIARY
WASHINGTON, DC 20510-6275

BRUCE A. COHEN, *Chief Counsel and Staff Director*
KOLAN L. DAVIS, *Republican Chief Counsel and Staff Director*

May 4, 2011

Via Electronic Transmission

Henri R. Manasse, Jr.
Executive Vice President and Chief Executive Officer
American Society of Health-System Pharmacists
7272 Wisconsin Avenue
Bethesda, MD 20814

Dear Mr. Manasse:

In December 2009, I asked for an accounting of industry funding that American Society of Health-System Pharmacists (ASHSP) receives from pharmaceutical and medical device companies as well as foundations established by these companies or the insurance industry. I appreciate your response, which I have attached to this letter. I write today to follow up on any efforts by your organization to improve transparency and accountability in its relationships with the pharmaceutical and device industries.

As I stated in my previous letter, I started my inquiry, in part, as a result of accounts documenting the lack of transparency in financial relationships between the pharmaceutical industry and nonprofit health and medical organizations. Specifically, I cited the April 2008 article in *The Wall Street Journal*, which reported that industry representatives, including ten major drug companies, had formed a coalition to promote looser restrictions on off-label marketing.¹ The coalition had asked the National Alliance on Mental Illness (NAMI) to speak in favor of this issue.

In response to my concerns in my April 2009 letter to NAMI, NAMI began to voluntarily disclose to the public any amount of funding exceeding \$5,000 that it received from pharmaceutical companies and foundations on its website. Further, NAMI began to provide a brief description of the purpose of the funding on its website. I commend NAMI for its leadership and had hoped that when I reached out to your organization and 32 others, your organization would follow NAMI's example and begin posting similar funding information on ASHSP's website.

As of the date of this letter, it appears that no additional information regarding your organization's industry funding has been posted on the ASHSP's website. If ASHSP is currently taking steps to enhance the transparency of its financial relationships with the pharmaceutical

¹ Alicia Mundy, "Off-Label Use of Drugs Gets a Push --- Big Pharma Lobbies Washington to Relax Rules on Marketing," *The Wall Street Journal*, April 18, 2008.

and device industries, I would appreciate information regarding those steps. If not, please explain why your organization does not support the disclosure of funding it receives from pharmaceutical and device companies.

The Medicare Payment Advisory Commission (MedPAC) recommended in a report to Congress in March 2009 that Congress require that pharmaceutical and device companies report their financial relationships with physician groups, patient organizations, and others. More specifically MedPAC said the following:

Given the potential benefits of public reporting, we recommend that the Congress mandate the reporting of comprehensive information on industry relationships with physicians and other health care entities and that the Secretary post this information on a public searchable website.²

MedPAC then went on to say in Recommendation 5-1 that:

The Congress should require all manufacturers and distributors of drugs, biologicals, medical devices, and medical supplies (and their subsidiaries) to report to the Secretary their financial relationship with:...physician groups and other prescribers...patient organizations; and professional organizations.³

I look forward to working with you and other health and medical organizations to further increase sunshine on financial relationships.

Thank you for your cooperation and attention in this matter. I would appreciate a response by May 25, 2011. If you have any questions, please do not hesitate to contact Brian Downey for the Committee on the Judiciary at (202) 224-5225.

Sincerely,



Charles E. Grassley
Ranking Member

Attachments

² Medicare Payment Advisory Commission, "Public reporting of physicians' financial relationships," Report to Congress: Medicare Payment Policy, March 2009.

³ *Id.*

Attachment



January 21, 2010

Via Electronic Transmission

The Honorable Charles E. Grassley
Ranking Member
Committee on Finance
United States Senate
Washington, DC 20510-6200

Dear Senator Grassley:

I am pleased to respond to your request regarding industry funding, policies for accepting such funding, and disclosure requirements for our top executives and board members.

Please note that ASHP's fiscal year begins on June 1 and ends the following May 31. We have provided the enclosed information beginning January 1, 2006, through the end of our 2009 fiscal year.

ASHP represents pharmacists who practice in hospitals and health systems. The Society's 35,000 members include pharmacists and pharmacy technicians who practice in a variety of health-system settings, including inpatient, outpatient, home care, and long-term-care settings, as well as pharmacy students. Pharmacists in hospitals and health systems are experts in medication use who serve on interdisciplinary patient-care teams.

We appreciate the opportunity to be of assistance to you. If you have any questions, please do not hesitate to contact Fern Zappala, General Counsel (fzappala@ashp.org or 301-664-8690) or Brian Meyer, Director, Government Affairs (bmeyer@ashp.org or 301-664-8698).

Sincerely,

Henri R. Manasse, Jr., Ph.D., Sc.D.
Executive Vice President and Chief Executive Officer

cc: ASHP Board of Directors

TOGETHER WE MAKE A GREAT TEAM

ASHP Industry Funding 2006-2009

ASHP Industry Funding, 2006 - 2009

Year	Company	Amount	Reason
FY06	Allergan	\$ 87,700	Commercial Support for Certified CPE Activity for pharmacists on revenue cycle management in the hospital pharmacy
FY06	Amgen	\$ 79,500	Commercial Support for Certified CPE Activity for pharmacists on oncology care
FY06	Amgen	\$ 50,500	Commercial Support for Certified CPE Activity for pharmacists on oncology care
FY06	Amgen	\$ 9,000	Development of online resource center for pharmacists on Medicare reimbursement changes
FY06	Baxter	\$ 55,000	Certified Continuing Education intended to assist pharmacists in improving patient care
FY06	Baxter	\$ 25,950	Development of article describing research on medication barcoding
FY06	Baxter	\$ 49,500	Commercial Support for Certified CPE Activity for pharmacists on sterile compounding and USP <797> compliance
FY06	Bristol-Myers Squibb	\$ 34,900	Commercial Support for Certified CPE Activity for pharmacists on management of acute coronary syndromes
FY06	CV Therapeutics	\$ 99,550	Commercial Support for Certified CPE Activity for pharmacists on management of angina
FY06	GlaxoSmithKline	\$ 39,400	Commercial Support for Certified CPE Activity for pharmacists on Demonstrating the Value of the Pharmacy Department in Today's Health System
FY06	GlaxoSmithKline	\$ 34,900	Certified Continuing Education intended to assist pharmacists in improving patient care
FY06	Hospira	\$ 99,765	Development of Patient education video program on Medication Safety
FY06	Hospira	\$ 120,350	certified Continuing Education for critical-care nurses at American Association of Critical-Care Nurses National Teaching Institute 2006
FY06	McKesson	\$ 12,810	Purchase of reprints of article from the <i>American Journal of Health-System Pharmacy</i>
FY06	McKesson	\$ 15,900	Purchase of reprints of article from the <i>American Journal of Health-System Pharmacy</i>
FY06	Merck	\$ 110,000	Commercial Support for Certified CPE Activity for pharmacists (publication) on systemic fungal infections, dyslipidemia, antimicrobial resistance, adult immunization, and management of chemotherapy-induced nausea and vomiting
FY06	Merck	\$ 129,050	Commercial Support for Certified CPE Activity for pharmacists (Internet activities) on systemic fungal infections, dyslipidemia, antimicrobial resistance, adult immunization, and management of chemotherapy-induced nausea and vomiting
FY06	Merck	\$ 123,000	Commercial Support for Certified CPE Activities for pharmacists on management of systemic fungal infections
FY06	OrthoBiotech	\$ 180,203	Commercial Support for Certified CPE Activities for pharmacists on Anemia and Chronic Kidney Disease
FY06	Amgen	\$ 75,200	Commercial Support for Certified CPE Activity for pharmacists on changes in Medicare reimbursement
FY06	Allergan	\$ 8,000	Purchase of reprints of article from the <i>American Journal of Health-System Pharmacy</i>
FY06	Roche	\$ 49,500	Commercial Support for Certified CPE Activity for pharmacists on managing cytomegalovirus in transplant patients

Year	Company	Amount	Reason
FY06	Roche	\$ 99,550	Commercial Support for Certified CPE Activity for pharmacists on the management of osteoporosis
FY06	sanofi aventis	\$ 34,500	Commercial Support for Certified CPE Activity for pharmacists on prevention and management of deep-vein thrombosis
FY06	sanofi aventis	\$ 188,948	Commercial Support for Certified CPE Activity for pharmacists on cardiometabolic syndrome
FY06	sanofi aventis	\$ 111,100	Commercial Support for supplement to the <i>American Journal of Health-System Pharmacy</i> (Certified CPE Activity for pharmacists) on managing colorectal cancer
FY06	sanofi aventis	\$ 34,500	Commercial Support for Certified CPE Activity for pharmacists) on managing colorectal cancer
FY06	Scios	\$ 34,500	Commercial Support for Certified CPE Activity for pharmacists on acute decompensated heart failure
FY06	Scios	\$ 360,000	Commercial Support for Certified CPE Activity for pharmacists on acute decompensated heart failure
FY06	Scios	\$ 90,506	Commercial Support for Certified CPE Activity for pharmacists on acute decompensated heart failure
FY06	Sepracor	\$ 111,100	Commercial Support for Certified CPE Activity for pharmacists on asthma management
FY06	Sepracor	\$ 75,800	Commercial Support for Certified CPE Activity for pharmacists on asthma management
FY06	Wyeth	\$ 51,076	Commercial Support for Certified CPE Activity for pharmacists on antimicrobial therapy in hospitals
FY06	Amgen	\$ 50,000	Commercial Support for Oncology Certification Preparatory Course (Certified CPE Activity)
FY06	Amgen	\$ 4,676	Commercial Support for Great Expectations, ASHP's certified CPE conference for new practitioners
FY06	Amgen	\$ 10,000	Meeting Sponsorship - meeting bags for ASHP Summer Meeting
FY06	Amgen	\$ 30,000	Meeting Sponsorship - meeting bags for ASHP Midyear Clinical Meeting
FY06	Amgen	\$ 100,000	Meeting Sponsorship - Shuttle busses
FY06	Astra Zeneca	\$ 30,600	Sponsorship for distribution of ASHP meeting handouts and slides on CD ROM
FY06	Astra Zeneca	\$ 54,000	Support for ASHP State Affiliate Presidential Officers' Training Sessions
FY06	Astra Zeneca	\$ 110,000	Meeting Sponsorship - Internet "café" Internet access and computer terminals
FY06	Baxter	\$ 20,000	Meeting Sponsorship - name badge lanyards for ASHP Midyear Clinical meeting
FY06	Baxter	\$ 23,000	Meeting Sponsorship - Exhibitor map Z-card
FY06	Eli Lilly	\$ 20,000	Meeting Sponsorship - aisle signs for exhibit hall
FY06	Merck	\$ 77,860	Support to conduct and publish ASHP National Survey of Pharmacy Practice in Hospitals
FY06	Ortho McNeil	\$ 90,539	Commercial Support for Psychiatric Pharmacy Certification Preparatory Course (Certified CPE Activity)
FY06	Abbott	\$ 18,291	Commercial support to fund database enhancement for the ASHP Drug Shortages website
FY07	Abbott	\$ 51,821	Advisory meeting of hospital pharmacy directors
FY07	Takeda	\$ 49,150	Advisory meeting of hospital pharmacy directors
FY07	Amgen	\$ 50,000	Commercial Support for ASHP Annual Conference for Leaders in Health-System Pharmacy, a certified CPE activity

Year	Company	Amount	Reason
FY07	Roche	\$ 50,000	Commercial Support for ASHP Annual Conference for Leaders in Health-System Pharmacy, a certified CPE activity
FY07	Lilly	\$ 25,000	Commercial Support for ASHP Annual Conference for Leaders in Health-System Pharmacy, a certified CPE activity
FY07	Wyeth	\$ 25,000	Commercial Support for ASHP Annual Conference for Leaders in Health-System Pharmacy, a certified CPE activity
FY07	Amgen	\$ 80,000	Commercial Support for ASHP Pharmacy Residency Preceptors' Conference, a certified CPE activity
FY07	Baxter	\$ 81,200	Commercial Support for Best Practices in Health-System Pharmacy Practice Awards Program and Poster Session
FY07	Amgen	\$ 134,350	Commercial Support for certified c.e. activity for pharmacists on colorectal cancer
FY07	Amgen	\$ 82,000	Commercial Support for certified c.e. activity for pharmacists on the Medicare Modernization Act
FY07	Berlex	\$ 56,600	Commercial Support for certified C.E. activity for pharmacists, physicians, nurses, and radiologic technologists on safety issues with contrast media agents
FY07	Amgen	\$ 150,000	Commercial Support for certified c.e. activity for pharmacy residents to facilitate transition into practice
FY07	Adolor	\$ 122,679	Commercial Support for certified c.e. activity on post-operative GI management
FY07	Merck	\$ 157,860	Commercial Support for certified C.P.E. activities for pharmacists
FY07	Merck	\$ 807,420	Commercial Support for certified C.P.E. activities for pharmacists at ASHP Midyear Clinical Meeting
FY07	Baxter	\$ 58,000	Commercial Support for certified C.P.E. activities for pharmacists at state affiliate meetings on USP 797 sterile compounding requirements
FY07	Scios	\$ 137,800	Commercial Support for certified C.P.E. activities for pharmacists on acute compensated heart failure
FY07	Sanofi Aventis	\$ 358,315	Commercial Support for certified C.P.E. activities for pharmacists on thromboembolic disorders
FY07	Sanofi Aventis	\$ 115,850	Commercial Support for certified C.P.E. activities for pharmacists on thromboembolic disorders
FY07	Sanofi Aventis	\$ 148,479	Commercial Support for certified C.P.E. activities for pharmacists on thromboembolic disorders
FY07	Sanofi Aventis	\$ 37,500	Commercial Support for certified C.P.E. activities for pharmacists on thromboembolic disorders
FY07	Merck	\$ 134,640	Commercial Support for certified C.P.E. activity (publication) for pharmacists
FY07	Novo Nordisk	\$ 101,663	Commercial Support for certified C.P.E. activity for pharmacists at American Pharmacists Assn. Meeting on diabetes management
FY07	Scios	\$ 132,887	Commercial Support for certified C.P.E. activity for pharmacists on acute compensated heart failure
FY07	Scios	\$ 94,900	Commercial Support for certified C.P.E. activity for pharmacists on acute compensated heart failure
FY07	Bristol-Myers Squibb	\$ 109,869	Commercial Support for certified C.P.E. activity for pharmacists on acute coronary syndromes
FY07	Bristol-Myers Squibb	\$ 98,771	Commercial Support for certified C.P.E. activity for pharmacists on acute coronary syndromes

Year	Company	Amount	Reason
FY07	Bristol-Myers Squibb	\$ 47,518	Commercial Support for certified C.P.E. activity for pharmacists on acute coronary syndromes
FY07	Baxter	\$ 25,700	Commercial Support for certified C.P.E. activity for pharmacists on anesthesia
FY07	Merck	\$ 80,800	Commercial Support for certified C.P.E. activity for pharmacists on changes in Medicare part B reimbursement in hospitals
FY07	Merck	\$ 97,100	Commercial Support for certified C.P.E. activity for pharmacists on diabetes management
FY07	Merck	\$ 98,600	Commercial Support for certified C.P.E. activity for pharmacists on diabetes management
FY07	Merck	\$ 59,500	Commercial Support for certified C.P.E. activity for pharmacists on diabetes management
FY07	Novo Nordisk	\$ 159,176	Commercial Support for certified C.P.E. activity for pharmacists on diabetes management
FY07	Novo Nordisk	\$ 50,000	Commercial Support for certified C.P.E. activity for pharmacists on diabetes management
FY07	Lilly	\$ 56,250	Commercial Support for certified C.P.E. activity for pharmacists on diabetic retinopathy
FY07	Lilly	\$ 59,500	Commercial Support for certified C.P.E. activity for pharmacists on diabetic retinopathy
FY07	Baxter	\$ 74,300	Commercial Support for certified C.P.E. activity for pharmacists on emergency preparedness
FY07	Omnicell	\$ 75,000	Commercial Support for certified C.P.E. activity for pharmacists on improving safety in medication-use through automation
FY07	Lilly	\$ 100,400	Commercial Support for certified C.P.E. activity for pharmacists on inpatient glycemic control
FY07	Lilly	\$ 63,000	Commercial Support for certified C.P.E. activity for pharmacists on inpatient glycemic control
FY07	Baxter	\$ 63,500	Commercial Support for certified C.P.E. activity for pharmacists on intravenous therapy management
FY07	Ortho Biotech	\$ 83,613	Commercial Support for certified C.P.E. activity for pharmacists on management of anemia in chronic kidney disease
FY07	Roche	\$ 128,481	Commercial Support for certified C.P.E. activity for pharmacists on management of anemia in chronic kidney disease
FY07	Merck	\$ 98,600	Commercial Support for certified C.P.E. activity for pharmacists on management of post-operative nausea and vomiting
FY07	Merck	\$ 59,500	Commercial Support for certified C.P.E. activity for pharmacists on management of post-operative nausea and vomiting
FY07	Merck	\$ 125,000	Commercial Support for certified C.P.E. activity for pharmacists on management of post-operative nausea and vomiting
FY07	Amgen	\$ 89,650	Commercial Support for certified C.P.E. activity for pharmacists on Medicare changes
FY07	Amgen	\$ 58,300	Commercial Support for certified C.P.E. activity for pharmacists on Medicare changes
FY07	Diagnostica Stago	\$ 85,600	Commercial Support for certified C.P.E. activity for pharmacists on monitoring of patients on anticoagulation therapy
FY07	Diagnostica Stago	\$ 48,835	Commercial Support for certified C.P.E. activity for pharmacists on monitoring of patients on anticoagulation therapy
FY07	Baxter	\$ 70,800	Commercial Support for certified C.P.E. activity for pharmacists on nutrition Commercial Support
FY07	Baxter	\$ 58,200	Commercial Support for certified C.P.E. activity for pharmacists on pain management
FY07	Merck	\$ 87,700	Commercial Support for certified C.P.E. activity for pharmacists on pain management

Year	Company	Amount	Reason
FY07	GlaxoSmith Kline	\$ 91,400	Commercial Support for certified C.P.E. activity for pharmacists on Preparing the Health System for an Influenza Pandemic
FY07	GlaxoSmith Kline	\$ 89,750	Commercial Support for certified C.P.E. activity for pharmacists on Preparing the Health System for an Influenza Pandemic
FY07	Berlex	\$ 151,081	Commercial Support for certified C.P.E. activity for pharmacists on safety issues with contrast media agents
FY07	Merck	\$ 98,600	Commercial Support for certified C.P.E. activity for pharmacists on systemic antifungal therapy in critically ill patients
FY07	CV Therapeutics	\$ 45,000	Commercial Support for certified C.P.E. activity for pharmacists on the management of angina
FY07	CV Therapeutics	\$ 115,500	Commercial Support for certified C.P.E. activity for pharmacists on the management of angina
FY07	Sepracor	\$ 6,060	Commercial Support for certified C.P.E. activity for pharmacists on the management of asthma
FY07	Sepracor	\$ 73,800	Commercial Support for certified C.P.E. activity for pharmacists on the management of asthma
FY07	Sepracor	\$ 78,750	Commercial Support for certified C.P.E. activity for pharmacists on the management of asthma
FY07	Novo Nordisk	\$ 69,614	Commercial Support for certified C.P.E. activity for pharmacists on the management of hemorrhagic stroke
FY07	Novo Nordisk	\$ 61,300	Commercial Support for certified C.P.E. activity for pharmacists on the management of hemorrhagic stroke
FY07	Berlex	\$ 99,080	Commercial Support for expert panel discussion on compliance with The Joint Commission medication management standards in dealing with contrast media agents
FY07	Amgen	\$ 176,438	Commercial Support for Great Expectations, ASHP's certified CPE conference for new practitioners
FY07	Roche	\$ 294,000	Commercial Support for interdisciplinary certified c.e. activity for pharmacists, physicians, nurses, nurse practitioners, family physicians to improve safety in the use of oral chemotherapy agents
FY07	Amgen	\$ 65,189	Commercial Support for Oncology Certification Preparatory Course (Certified CPE Activity)
FY07	Ortho McNeil Janssen	\$ 35,261	Commercial Support for Psychiatric Pharmacy Certification Preparatory Course (Certified CPE Activity)
FY07	Johnson & Johnson	\$ 23,800	Commercial Support for Psychiatric Pharmacy Certification Preparatory Course (Certified CPE Activity)
FY07	Lilly	\$ 10,000	Commercial Support for Psychiatric Pharmacy Certification Preparatory Course (Certified CPE Activity)
FY07	Lilly	\$ 135,200	Commercial Support for supplement to the American Journal of Health-System Pharmacy on inpatient glycemic control
FY07	Amgen	\$ 121,000	Commercial Support for supplement to the <i>American Journal of Health-System Pharmacy</i> on Medicare changes
FY07	McKesson	\$ 84,310	Commercial Support to convene an expert panel meeting on the topic of the future of pharmacy informatics in hospitals

Year	Company	Amount	Reason
FY07	McKesson	\$ 42,030	Development of article in the <i>American Journal of Health-System Pharmacy</i> on strategies for a high-performance pharmacy department
FY07	Roche	\$ 121,100	Development of article in the <i>American Journal of Health-System Pharmacy</i> on strategies for a high-performance pharmacy department
FY07	Roche	\$ 133,500	Development of article in the <i>American Journal of Health-System Pharmacy</i> on strategies for a high-performance pharmacy department
FY07	Amgen	\$ 18,000	Development of online resources to assist pharmacists with a practice-related issue
FY07	Team Pharmaceuticals	\$ 4,000	Development of web-based resource center on chronic sinusitis
FY07	ImaRx	\$ 34,600	Focus group discussion on issues related to thrombolytic therapy in the hospital setting
FY07	Endo	\$ 13,919	Meeting of expert panel on pain management
FY07	Roche	\$ 50,000	Meeting Sponsorship - aisle signs for exhibit hall
FY07	Roche	\$ 34,475	Meeting Sponsorship - Exhibitor map Z-card
FY07	Amgen	\$ 25,000	Meeting Sponsorship - Hotel key cards
FY07	AstraZeneca	\$ 110,000	Meeting Sponsorship - Internet access and computer terminals
FY07	Adolor	\$ 40,000	Meeting Sponsorship - lead retrieval cards
FY07	Roche	\$ 40,000	Meeting Sponsorship - massage chairs
FY07	Amgen	\$ 35,000	Meeting Sponsorship - meeting bags for ASHP Midyear Clinical Meeting
FY07	Amgen	\$ 10,000	Meeting Sponsorship - meeting bags for ASHP Summer Meeting
FY07	Baxter	\$ 40,000	Meeting Sponsorship - name badge lanyards for ASHP Midyear Clinical meeting
FY07	Baxter	\$ 5,000	Meeting Sponsorship - namebadge lanyards for ASHP Summer Meeting
FY07	Amgen	\$ 100,000	Meeting Sponsorship - Shuttle busses
FY07	Ortho Biotech	\$ 111,198	Publication of Supplement in the <i>American Journal of Health-System Pharmacy</i> on management of anemia in chronic kidney disease
FY07	Amgen	\$ 53,956	Sponsorship for development and distribution of video on pharmacy residency training
FY07	AstraZeneca	\$ 55,400	Sponsorship for distribution of ASHP meeting handouts and slides on CD ROM
FY07	Wyeth	\$ 5,000	Sponsorship of ASHP Presidential Award
FY07	Roche	\$ 85,000	Sponsorship of daily electronic News broadcast from national meeting
FY07	Amgen	\$ 33,000	Sponsorship of digital meeting guide for national meeting
FY07	Amgen	\$ 30,000	Sponsorship of digital meeting guide for national meeting
FY07	AstraZeneca	\$ 54,000	Support for ASHP State Affiliate Presidential Officers' Training Sessions
FY07	Merck	\$ 77,860	Support to conduct and publish ASHP National Survey of Pharmacy Practice in Hospitals
FY08	Merck	\$ 766,860	Commercial Support for certified c.e. activities for pharmacists on dyslipidemia, diabetes, immunizations, and antimicrobial stewardship
FY08	Sanofi Aventis	\$ 357,800	Commercial Support for certified C.P.E. activities for pharmacists on thromboembolic disorders
FY08	Sanofi Aventis	\$ 200,000	Commercial Support for initiative (tools, resources, expert panel meeting) to train pharmacists and motivate them to take a leadership role in patient-care quality improvement activities based on national guidelines and performance measures (http://www.ashp.org/qii)

Year	Company	Amount	Reason
FY08	Sanofi Aventis	\$ 166,900	Commercial Support for certified C.P.E. activities for pharmacists on thromboembolic disorders
FY08	Amgen	\$ 149,680	Commercial Support for certified C.P.E. activities for pharmacists on change in Medicare reimbursement
FY08	Amgen	\$ 188,914	Commercial Support for certified C.P.E. activities for pharmacists on febrile neutropenia in cancer patients
FY08	Novo Nordisk	\$ 179,138	Commercial Support for certified C.E. activities for pharmacists, physicians, and nurses on transfusion therapy
FY08	Novo Nordisk	\$ 174,182	Commercial Support for certified C.P.E. activity for pharmacists on diabetes management
FY08	Sanofi Aventis	\$ 169,530	Commercial Support for certified C.P.E. activities for pharmacists on thromboembolic disorders
FY08	Bayer	\$ 169,913	Commercial Support for certified C.P.E. activity for pharmacists on safety in the use of contrast media
FY08	Amgen	\$ 111,100	Commercial Support for supplement to the <i>American Journal of Health-System Pharmacy</i> (certified C.P.E. activity for pharmacists) on Medicare reimbursement changes
FY08	Adolor	\$ 118,370	Commercial Support for supplement to the <i>American Journal of Health-System Pharmacy</i> (certified C.P.E. activity for pharmacists) on postoperative ileus
FY08	Roche	\$ 113,097	Commercial Support for supplement to the <i>American Journal of Health-System Pharmacy</i> (certified C.P.E. activity for pharmacists) on anemia in chronic kidney disease
FY08	Amgen	\$ 156,300	Commercial Support for certified c.e. activity for pharmacy residents to facilitate transition into practice
FY08	Adolor	\$ 153,717	Commercial Support for certified C.P.E. activity for pharmacists on postoperative bowel dysfunction
FY08	Adolor	\$ 245,989	Commercial Support for certified C.M.E. activities for physicians at American College of Surgeons Annual Meeting on postoperative bowel dysfunction
FY08	Sanofi Aventis	\$ 95,000	Commercial Support for initiative (resources, information, training) for pharmacists to enable them to engage in quality improvement activities focused on improving patient care (www.ashp.org/qii)
FY08	Amgen	\$ 119,425	Commercial Support for supplement to the <i>American Journal of Health-System Pharmacy</i> (certified C.P.E. activity for pharmacists) on changes in Medicare reimbursement
FY08	Amgen	\$ 47,514	Commercial Support for ASHP Annual Conference for Leaders in Health-System Pharmacy, a certified CPE activity
FY08	Lilly	\$ 47,514	Commercial Support for ASHP Annual Conference for Leaders in Health-System Pharmacy, a certified CPE activity
FY08	Roche	\$ 47,514	Commercial Support for ASHP Annual Conference for Leaders in Health-System Pharmacy, a certified CPE activity
FY08	Wyeth	\$ 47,514	Commercial Support for ASHP Annual Conference for Leaders in Health-System Pharmacy, a certified CPE activity

Year	Company	Amount	Reason
FY08	Scios	\$ 149,604	Commercial Support for certified C.P.E. activity for pharmacists on acute decompensated heart failure
FY08	Lilly	\$ 111,100	Commercial Support for supplement to the American Journal of Health-System Pharmacy (certified C.P.E. activity for pharmacists) on diabetic retinopathy
FY08	Allergan	\$ 177,600	Commercial Support for certified C.P.E. activity for pharmacists on regulatory and clinical considerations with biosimilars
FY08	Sanofi Aventis	\$ 111,589	Commercial Support for supplement to the American Journal of Health-System Pharmacy (certified C.P.E. activity for pharmacists) on prevention and management of deep vein thrombosis
FY08	Wyeth	\$ 102,630	Commercial Support for publication on particulate matter contamination in sterile compounding
FY08	Bristol-Myers Squibb/Sanofi	\$ 144,950	Commercial Support for certified C.P.E. activity for pharmacists on acute coronary syndromes
FY08	Merck	\$ 120,900	Commercial Support for certified c.e. activities for pharmacists on dyslipidemia, diabetes, immunizations, and antimicrobial stewardship
FY08	Merck	\$ 96,000	Commercial Support for certified c.e. activities for pharmacists on dyslipidemia, diabetes, immunizations, and antimicrobial stewardship
FY08	Sepracor	\$ 102,833	Commercial Support for certified C.P.E. activity for pharmacists on chronic obstructive pulmonary disease
FY08	Merck	\$ 102,050	Commercial Support for certified C.P.E. activity for pharmacists on systemic fungal infections
FY08	Bristol-Myers Squibb/ Sanofi Aventis Partnership	\$ 121,817	Commercial Support for certified C.P.E. activity for pharmacists on acute coronary syndromes
FY08	Vestara Web	\$ 100,000	Commercial Support for certified C.P.E. activity for pharmacists on regulations in pharmaceutical waste management
FY08	Sanofi Aventis	\$ 109,000	Commercial Support for certified C.P.E. activity for pharmacists on acute coronary syndromes
FY08	Roche	\$ 100,469	Commercial Support for certified C.P.E. activity for pharmacists on anemia in chronic kidney disease
FY08	Merck	\$ 107,150	Commercial Support for certified C.P.E. activity for pharmacists on HIV therapy
FY08	Bayer	\$ 99,080	Commercial Support for expert panel meeting on safety issues with contrast media
FY08	Novo Nordisk	\$ 80,515	Commercial Support for certified C.P.E. activity for pharmacists on transfusion medicine
FY08	Merck	\$ 107,150	Commercial Support for certified C.P.E. activity for pharmacists on diabetes management
FY08	Merck	\$ 84,975	Commercial Support for certified C.P.E. activity for pharmacists on diabetes management
FY08	Baxter	\$ 117,500	Commercial Support for Best Practices in Health-System Pharmacy Practice Awards Program and Poster Session
FY08	Baxter	\$ 77,910	Commercial Support for certified C.P.E. activity for pharmacists on prevention of medication errors with high-alert medications
FY08	OrthoBiotech	\$ 95,230	Commercial Support for certified C.P.E. activity for pharmacists on anemia management

Year	Company	Amount	Reason
FY08	Sepracor	\$ 81,250	Commercial Support for certified C.P.E. activity for pharmacists on chronic obstructive pulmonary disease
FY08	GlaxoSmithKline	\$ 96,250	Commercial Support for certified C.P.E. activity for pharmacists on antimicrobial resistance in hospitals
FY08	Wyeth	\$ 102,560	Commercial Support for certified C.P.E. activity for pharmacists on particulate matter contamination in sterile compounding
FY08	Baxter	\$ 86,365	Commercial Support for certified C.P.E. activity for pharmacists on malnutrition in hospitalized patients
FY08	Amgen	\$ 84,400	Commercial Support for certified C.P.E. activity for pharmacists on Medicare reimbursement
FY08	Baxter	\$ 76,605	Commercial Support for certified C.P.E. activity for pharmacists on medication safety
FY08	Bristol-Myers Squibb	\$ 90,504	Commercial Support for certified C.E. activity for pharmacists for case managers on acute coronary syndromes
FY08	Baxter	\$ 65,000	Commercial Support for certified C.P.E. activity for pharmacists on nutrition support
FY08	Roche	\$ 61,662	Commercial Support for certified C.P.E. activity for pharmacists on anemia in chronic kidney disease
FY08	Bayer	\$ 75,500	Commercial Support for certified C.P.E. activity for pharmacists on safety in the use of contrast media
FY08	Scios	\$ 75,500	Commercial Support for certified C.P.E. activity for pharmacists on acute decompensated heart failure
FY08	Bristol-Myers Squibb/ Sanofi Aventis Partnership	\$ 69,500	Commercial Support for certified C.P.E. activity for pharmacists on acute coronary syndromes
FY08	Berlex	\$ 64,000	Commercial Support for certified C.P.E. activities for pharmacists on safety in the use of contrast media
FY08	Baxter	\$ 57,500	Commercial Support for certified C.P.E. activity for pharmacists on medication safety
FY08	Roche	\$ 89,000	Sponsorship of daily electronic News broadcast from national meeting
FY08	OrthoBiotech	\$ 62,500	Commercial Support for certified C.P.E. activity for pharmacists on anemia in chronic kidney disease
FY08	Adolor	\$ 65,500	Commercial Support for certified C.P.E. activity for pharmacists on postoperative bowel dysfunction
FY08	Bristol-Myers Squibb	\$ 90,080	Commercial Support for certified C.P.E. activity at American College of Clinical Pharmacy national meeting on acute coronary syndromes
FY08	Novo Nordisk	\$ 73,441	Commercial Support for certified C.P.E. activity for pharmacists on transfusion medicine
FY08	Hospira	\$ 39,500	Commercial Support for certified C.P.E. activity for pharmacists on USP <797> requirements in sterile product compounding
FY08	Novo Nordisk	\$ 46,594	Commercial Support for certified C.P.E. activity for pharmacists on diabetes management

Year	Company	Amount	Reason
FY08	Hospira	\$ 54,436	Commercial Support for certified C.P.E. activity for pharmacists on USP <797> requirements in sterile product compounding
FY08	Novo Nordisk	\$ 114,051	Commercial Support for certified C.P.E. activity for managed care pharmacists on diabetes management
FY08	Sepracor	\$ 49,338	Support for advisory meeting
FY08	Allergan	\$ 71,825	Commercial Support for certified C.P.E. activity for pharmacists on neurotoxin therapy+D95
FY08	Novo Nordisk	\$ 40,000	Commercial Support for certified C.P.E. activity for pharmacists on diabetes management
FY08	Novo Nordisk	\$ 44,500	Commercial Support for certified C.P.E. activity for pharmacists on diabetes management
FY08	Amgen	\$ 30,000	Sponsorship of digital meeting guide for national meeting
FY08	Wyeth	\$ 56,980	Support for expert panel meeting on particulate matter in compounded i.v. admixtures
FY08	Baxter	\$ 22,630	Development of article in the <i>American Journal of Health-System Pharmacy</i>
FY08	Baxter	\$ 20,000	Commercial Support for development and publication of discussion guide on USP <797> requirements for sterile compounding
FY08	Amgen	\$ 10,000	Commercial Support for certified C.P.E. activity for pharmacists on Medicare reimbursement
FY08	Takeda	\$ 50,000	Commercial Support for interdisciplinary certified C.E. conference for physicians, pharmacists, and nurses on health care disparities in minority populations
FY08	Amgen	\$ 32,000	Commercial Support for interdisciplinary certified C.E. conference for physicians, pharmacists, and nurses on health care disparities in minority populations
FY08	Bristol-Myers Squibb	\$ 32,000	Commercial Support for interdisciplinary certified C.E. conference for physicians, pharmacists, and nurses on health care disparities in minority populations
FY08	AstraZeneca	\$ 25,000	Commercial Support for interdisciplinary certified C.E. conference for physicians, pharmacists, and nurses on health care disparities in minority populations
FY08	Pfizer	\$ 15,000	Commercial Support for interdisciplinary certified C.E. conference for physicians, pharmacists, and nurses on health care disparities in minority populations
FY08	Lilly	\$ 62,950	Commercial Support for interdisciplinary certified C.E. conference for physicians, pharmacists, and nurses on health care disparities in minority populations
FY08	Merck	\$ 10,000	Commercial Support for interdisciplinary certified C.E. conference for physicians, pharmacists, and nurses on health care disparities in minority populations
FY08	Amgen	\$ 133,684	Commercial Support for Great Expectations, ASHP's certified CPE conference for new practitioners
FY08	Merck	\$ 104,898	Support to conduct and publish ASHP National Survey of Pharmacy Practice in Hospitals
FY08	Amgen	\$ 1,517	Commercial Support for ASHP Residency Preceptors Conference, a certified C.P.E. activity
FY08	Wyeth	\$ 9,167	Sponsorship of ASHP Presidential Award
FY08	Amgen	\$ 9,044	Sponsorship for development and distribution of video on pharmacy residency training
FY08	Astra Zeneca	\$ 54,000	Support for ASHP State Affiliate Presidential Officers' Training Sessions
FY08	Roche	\$ 15,000	Meeting Sponsorship - aisle signs for exhibit hall
FY08	Amgen	\$ 10,000	Meeting Sponsorship - meeting bags for ASHP Summer Meeting

Year	Company	Amount	Reason
FY08	Roche	\$ 20,000	Meeting Sponsorship - Internet access and computer terminals
FY08	Takeda	\$ 15,000	Meeting Sponsorship of Luncheon at ASHP Summer Meeting
FY08	Amgen	\$ 40,000	Meeting Sponsorship - meeting bags for ASHP Midyear Clinical Meeting
FY08	Astra Zeneca/Abraxis	\$ 110,000	Meeting Sponsorship - Internet access and computer terminals
FY08	Amgen	\$ 40,000	Meeting Sponsorship - Hotel key cards
FY08	Baxter	\$ 44,000	Meeting Sponsorship - name badge lanyards for ASHP Midyear Clinical meeting
FY08	Ortho McNeil	\$ 44,000	Meeting Sponsorship - lead retrieval cards
FY08	Teva	\$ 5,000	Meeting Sponsorship - Meeting Planner
FY08	Roche	\$ 27,500	Meeting Sponsorship - Exhibitor map Z-card
FY09	Amgen	\$ 46,667	Commercial Support for ASHP Annual Conference for Leaders in Health-System Pharmacy, a certified CPE activity
FY09	Lilly	\$ 46,667	Commercial Support for ASHP Annual Conference for Leaders in Health-System Pharmacy, a certified CPE activity
FY09	Otsuka	\$ 50,000	Commercial Support for ASHP Annual Conference for Leaders in Health-System Pharmacy, a certified CPE activity
FY09	Roche	\$ 46,667	Commercial Support for ASHP Annual Conference for Leaders in Health-System Pharmacy, a certified CPE activity
FY09	Amgen	\$ 92,383	Commercial Support for ASHP Residency Preceptors Conference, a certified C.P.E. activity
FY09	Amgen	\$ 98,550	Commercial Support for Best Practices in Health-System Pharmacy Practice Awards Program and Poster Session
FY09	Bristol-Myers Squibb	\$ 109,900	Commercial Support for certified C.E. activity for case managers on acute coronary syndromes at Case Management Society of America Annual Meeting
FY09	Amgen	\$ 155,934	Commercial Support for certified c.e. activity for pharmacy residents to facilitate transition into practice
FY09	Merck	\$ 622,722	Commercial Support for certified C.P.E. activities for pharmacists on dyslipidemia, diabetes, and antimicrobial stewardship
FY09	Merck	\$ 97,248	Commercial Support for certified C.P.E. activities for pharmacists on dyslipidemia, diabetes, and antimicrobial stewardship
FY09	Sanofi Aventis	\$ 197,335	Commercial Support for certified C.P.E. activities for pharmacists on management of osteoporosis
FY09	Sanofi Aventis	\$ 1,145,280	Commercial Support for certified C.P.E. activities for pharmacists on thromboembolic disorders
FY09	Sanofi Aventis	\$ 443,550	Commercial Support for certified C.P.E. activities for pharmacists on thromboembolic disorders
FY09	Sanofi Aventis	\$ 130,000	Commercial Support for certified C.P.E. activity at American College of Clinical Pharmacy for pharmacists on acute coronary syndromes
FY09	Bristol-Myers Squibb/ Sanofi Partnership	\$ 108,453	Commercial Support for certified C.P.E. activity for managed care pharmacists on acute coronary syndromes

Year	Company	Amount	Reason
FY09	Sanofi Aventis	\$ 36,300	Support for practice tools and resources to engage pharmacists in quality improvement activities regarding guidelines and patient care performance measures
FY09	Sanofi Aventis	\$ 68,250	Commercial Support for certified C.P.E. activity for pharmacists on venous thromboembolism
FY09	Bristol-Myers Squibb/ Sanofi Partnership	\$ 56,119	Commercial Support for certified C.P.E. activity for pharmacists on acute coronary syndromes
FY09	Sanofi Aventis	\$ 127,100	Commercial Support for certified C.P.E. activity for pharmacists on acute coronary syndromes
FY09	Sanofi Aventis	\$ 38,050	Commercial Support for certified C.P.E. activity for pharmacists on acute coronary syndromes
FY09	OrhtoBiotech	\$ 69,500	Commercial Support for certified C.P.E. activity for pharmacists on anemia management
FY09	OrhtoBiotech	\$ 106,400	Commercial Support for certified C.P.E. activity for pharmacists on anemia management
FY09	Ortho McNeil	\$ 155,280	Commercial Support for certified C.P.E. activity for pharmacists on anticoagulation therapy
FY09	Ortho McNeil	\$ 58,800	Commercial Support for certified C.P.E. activity for pharmacists on anticoagulation therapy
FY09	Sanofi Aventis	\$ 119,350	Commercial Support for certified C.P.E. activity for pharmacists on anticoagulation therapy in elderly patients
FY09	Sepracor	\$ 1,177	Commercial Support for certified C.P.E. activity for pharmacists on chronic obstructive pulmonary disease
FY09	Amgen	\$ 18,000	Commercial Support for certified C.P.E. activity for pharmacists on colorectal cancer
FY09	Amgen	\$ 111,100	Commercial Support for certified C.P.E. activity for pharmacists on colorectal cancer
FY10	Bristol-Myers Squibb	\$ 18,000	Commercial Support for certified C.P.E. activity for pharmacists on colorectal cancer
FY09	Bayer	\$ 40,500	Commercial Support for certified C.P.E. activity for pharmacists on contrast media use
FY09	Bristol-Myers Squibb/Sanofi	\$ 239,688	Commercial Support for certified C.P.E. activity for pharmacists on deep vein thrombosis and acute coronary syndromes
FY09	Novo Nordisk	\$ 195,006	Commercial Support for certified C.P.E. activity for pharmacists on diabetes management
FY09	Novo Nordisk	\$ 72,500	Commercial Support for certified C.P.E. activity for pharmacists on diabetes management
FY09	Allergan	\$ 78,511	Commercial Support for certified C.P.E. activity for pharmacists on emerging uses and safety issues with neurotoxins
FY09	Allergan	\$ 195,400	Commercial Support for certified C.P.E. activity for pharmacists on emerging uses and safety issues with neurotoxins
FY09	Hospira	\$ 44,000	Commercial Support for certified C.P.E. activity for pharmacists on ensuring safety with high-alert medications
FY09	Novo Nordisk	\$ 105,258	Commercial Support for certified C.P.E. activity for pharmacists on management of critical bleeding
FY09	Lilly	\$ 36,000	Commercial Support for certified C.P.E. activity for pharmacists on managing depression
FY09	Hospira	\$ 90,800	Commercial Support for certified C.P.E. activity for pharmacists on medication safety
FY09	Baxter	\$ 97,975	Commercial Support for certified C.P.E. activity for pharmacists on nutrition support in hospitalized patients
FY09	Baxter	\$ 70,000	Commercial Support for certified C.P.E. activity for pharmacists on nutrition support in hospitalized patients

Year	Company	Amount	Reason
FY09	GlaxoSmithKline	\$ 159,067	Commercial Support for certified C.P.E. activity for pharmacists on postoperative bowel dysfunction
FY09	GlaxoSmithKline	\$ 69,220	Commercial Support for certified C.P.E. activity for pharmacists on postoperative bowel dysfunction
FY09	Roche	\$ 102,000	Commercial Support for certified C.P.E. activity for pharmacists on rheumatoid arthritis
FY09	Roche	\$ 75,500	Commercial Support for certified C.P.E. activity for pharmacists on rheumatoid arthritis
FY09	Allergan	\$ 149,933	Commercial Support for certified C.P.E. activity for pharmacists on safety considerations with biosimilar agents
FY09	Bayer	\$ 89,773	Commercial Support for certified C.P.E. activity for pharmacists on safety in use of contrast media
FY09	Amgen	\$ 26,718	Commercial Support for certified C.P.E. activity for pharmacists on supportive care for cancer patients
FY09	Amgen	\$ 26,718	Commercial Support for certified C.P.E. activity for pharmacists on supportive care for cancer patients
FY09	Eisai	\$ 30,298	Commercial Support for certified C.P.E. activity for pharmacists on supportive care for cancer patients
FY09	Eisai	\$ 30,298	Commercial Support for certified C.P.E. activity for pharmacists on supportive care for cancer patients
FY09	Sanofi Aventis	\$ 30,298	Commercial Support for certified C.P.E. activity for pharmacists on supportive care for cancer patients
FY09	Sanofi Aventis	\$ 30,298	Commercial Support for certified C.P.E. activity for pharmacists on supportive care for cancer patients
FY09	Novo Nordisk	\$ 66,117	Commercial Support for certified C.P.E. activity for pharmacists on thromboembolic disorders
FY09	Novo Nordisk	\$ 16,581	Commercial Support for certified C.P.E. activity for pharmacists on transfusion medicine
FY09	Sanofi Aventis	\$ 317,000	Commercial Support for certified C.P.E. activity for pharmacists on tumor lysis syndrome in cancer patients
FY09	Amgen	\$ 136,163	Commercial Support for Great Expectations, ASHP's certified CPE conference for new practitioners
FY09	Sanofi Aventis	\$ 157,250	Commercial Support for initiative (resources, information, training) for pharmacists to enable them to engage in quality improvement activities focused on improving patient care (www.ashp.org/qii)
FY09	Baxter	\$ 60,000	Commercial Support for interdisciplinary conference on improving safety with intravenous medication use in hospitals
FY09	Hospira	\$ 15,000	Commercial Support for interdisciplinary conference on improving safety with intravenous medication use in hospitals
FY09	Amgen	\$ 25,000	Commercial Support for Oncology Certification Preparatory Course (Certified CPE Activity)

Year	Company	Amount	Reason
FY09	Berlex	\$ 119,450	Commercial Support for practice tools and resources for pharmacists on ensuring safety in use of contrast media in hospitals
FY09	Sanofi Aventis	\$ 229,910	Commercial Support for supplement to Journal of Managed Care Pharmacy (certified C.P.E. activity for pharmacists) on deep vein thrombosis and acute coronary syndromes
FY09	Sanofi Aventis	\$ 149,933	Commercial Support for supplement to the American Journal for Health-System Pharmacy (certified C.P.E. activity for pharmacists) on deep vein thrombosis and acute coronary syndromes
FY09	Roche	\$ 55,000	Meeting Sponsorship - aisle signs for exhibit hall ASHP Midyear Clinical Meeting
FY09	Amgen	\$ 15,000	Meeting Sponsorship - aisle signs for exhibit hall ASHP Summer Meeting
FY09	Roche	\$ 30,000	Meeting Sponsorship - Exhibitor map Z-card
FY09	Amgen	\$ 40,000	Meeting Sponsorship - Hotel key cards
FY09	Hospira	\$ 10,000	Meeting Sponsorship - Hotel key cards
FY09	Amgen	\$ 55,000	Meeting Sponsorship - Internet access and computer terminals
FY09	Amgen	\$ 20,000	Meeting Sponsorship - meeting bags for ASHP Summer Meeting
FY09	Amgen	\$ 105,000	Meeting Sponsorship - meeting bags for ASHP Summer Meeting
FY09	Lilly	\$ 46,000	Meeting Sponsorship - Meeting lead cards
FY09	Baxter	\$ 44,000	Meeting Sponsorship - name badge lanyards for ASHP Midyear Clinical meeting
FY09	Sagent	\$ 15,000	Meeting Sponsorship - name badge lanyards for ASHP Summer meeting
FY09	Amgen	\$ 23,737	Meeting Sponsorship - Reception at Midyear Clinical Meeting
FY09	Wyeth	\$ 5,833	Sponsorship of ASHP Presidential Award
FY09	Roche	\$ 93,000	Sponsorship of daily electronic News broadcast from national meeting
FY09	McKesson	\$ 50,000	Support to conduct and publish ASHP National Survey of hospital pharmacy informatics
FY09	Merck	\$ 63,900	Support to conduct and publish ASHP National Survey of Pharmacy Practice in Hospitals

*FY06 data cover the period from January 1, 2006, through May 31, 2006

C.P.E. activity: An educational event or intervention that is certified for continuing pharmacy education credit

C.M.E. activity: An educational event or intervention that is certified for continuing medical education credit for physicians